Health Care & Life Sciences » Biotechnology | Alder BioPharmaceuticals Inc.

Alder BioPharmaceuticals Inc. | Ownership

Companies that own Alder BioPharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Redmile Group LLC
6,505,766
9.52%
0
3.65%
06/30/2018
The Vanguard Group, Inc.
4,930,138
7.23%
-273,573
0%
06/30/2018
Wellington Management Co. LLP
4,899,955
7.18%
-88,523
0.02%
06/30/2018
BlackRock Fund Advisors
4,378,781
6.42%
-289,981
0%
06/30/2018
SSgA Funds Management, Inc.
3,331,252
4.88%
-965,045
0.01%
06/30/2018
Bellevue Asset Management AG
3,024,972
4.43%
58,500
0.79%
06/30/2018
Fidelity Management & Research Co.
2,401,565
3.52%
427,600
0%
06/30/2018
Partner Fund Management LP
2,229,709
3.27%
-296,897
0.7%
06/30/2018
T. Rowe Price Associates, Inc.
1,862,713
2.73%
778,410
0.01%
06/30/2018
Palo Alto Investors LP
1,853,101
2.72%
3,269
1.29%
06/30/2018

About Alder BioPharmaceuticals

View Profile
Address
11804 North Creek Parkway South
Bothell Washington 98011
United States
Employees -
Website http://www.alderbio.com
Updated 07/08/2019
Alder Biopharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company, which discovers, develops, and commercializes various therapeutic antibodies. Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine; and Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.